Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Omega Therapeutics, Inc. - Common Stock (NQ: OMGA )

0.2298 +0.0093 (+4.22%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Omega Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors
Former Merck veteran brings extensive expertise across corporate finance, business development and corporate licensing 
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics To Participate In Two Upcoming Investor Conferences
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics to Participate in the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and Fibrosis
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics to Participate in The Jefferies London Healthcare Conference
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics Presents New Preclinical Data Demonstrating Pre-Transcriptional Modulation of Multiple CXCL Genes by a Single Epigenomic Controller
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC
Combination of a MYC-targeting epigenomic controller with immune checkpoint or EGFR inhibitor enhanced anti-tumor activity in models of NSCLC 
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics Announces Two Poster Presentations on Liver Inflammation and Fibrosis at AASLD’s The Liver Meeting® 2023
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial on September 26
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics to Participate in Two Upcoming Investor Conferences
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics Announces Updates to its Board of Directors
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
From Omega Therapeutics
Via GlobeNewswire
Omega Therapeutics Appoints Chris Schade to its Board of Directors
Accomplished Industry Veteran Brings Deep Strategic and Operational Expertise 
From Omega Therapeutics
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS